Domainex is a drug discovery service company based in Cambridge UK providing protein expression, assay development and screening, hit generation (fragment/virtual screening), and integrated medicinal chemistry incorporating in vitro pharmacology, in vivo DMPK, computational design and synthetic/analytical chemistry.
Embassy Event Services (part of the Embasssy Freight Group)
Embassy Event Services ( as part of the Embassy Freight Group) are 100% committed to supporting all UK based Lifescience companies ( and BioPartner UK) in making all event logistics as simple, reliable , and cost effective as possible, with this in mind, we offer all BioPartner UK members personalised event logistic services and discounted freight costs. We are proud to be part of the BioPartner UK family and will continue to support UK Life science and the BioPartner UK membership on all their event logistic requirements – from shipping to stand building to customs formalities – nothing is left to chance!
We make it our business to deliver on our commitments with honesty and responsibility - we have an established event team providing a personal, dedicated service backed up by an advanced and flexible I.T. infrastructure. For the diverse requirements of our clients - our philosophy remains the same: to understand the clients needs, to accept the challenge given, and to deliver a first class service to all clients For further information contact – email@example.com
Epidarex Capital invests in early-stage, high growth life science and health technology companies in under-ventured markets within the UK and US. Epidarex funds the commercialization of ground-breaking research and new technologies to address large and unmet needs in today’s healthcare market.
ERA is able to contribute at any stage of product development, from discovery, through process development, non-clinical and clinical aspects, to regulatory approval and beyond. One of our recognised specialities is the design of a regulatory strategy, to cover part or all of the development process. Thus, our services include the following: Regulatory due diligence exercises for in- or out-licensing, interactions with regulatory agencies, such as pre-IND, pre-BLA and scientific advice procedures, clinical trial applications, marketing authorisation applications, including eCTD submissions, post-approval amendments or variations, advice on process development, including validation, input on characterisation and control, consulting on non-clinical and clinical strategy, facility inspections and support for establishment licensing.
Femeda is a UK based company focused on developing a range technically ground breaking medical devices for female urinary incontinence. 698 million women worldwide are affected by incontinence, yet many existing products focus on managing and treating the symptoms of urinary incontinence, rather than the underlying cause.
Femeda is focused on the launch of Pelviva™, a unique patented disposable medical device for the treatment of female incontinence. Pelviva™, uses reactive pulse technology to strengthen weak pelvic floor muscles to prevent leaks and control urge incontinence. Pelviva™ has been shown to clinically improve bladder control in 84% of women after 12 weeks of treatment.
Fusion Antibodies is a CMO that offers a range of services covering all stages of therapeutic and diagnostic antibody development from target discovery to delivery of lead optimized commercial candidates suitable for cGMP scale up.
Fusion provides contract services include...
- Antibody Humanization services
- Antibody Engineering Services
- Antibody sequencing Services
- Protein Expression & Purification Services
- Monoclonal Antibody services BLAST & Standard
- cGMP Services
IAG - Image Analysis Group
IA-Group is a strategic partner to bio-pharmacutical companies. We bring extensive therapeutic knowledge and regulatory expertise in strategic use of clinical imaging to enhance understanding of the mode of action, to increase the efficiency of clinical decisions and to accelerate drug development.
IA’s operations team leverage our global footprint and the next-generation cloud based proprietry platform Dynamika to de-risk trial execution and to ensure data quality and integrity. Our venture arm pioneer unique targeted investment and risk-sharing models to enable our clients to reach the next value inflection point faster. We fuse decades of theraputic insight and agile culture to meet today's speed and high standard of therapeutic innovation.
Strategic pharmaceutical and pre-clinical consulting services. Critical due diligence, rationalisation and evaluation of IP portfolios, academic research and early-stage/preclinical projects - ultimately looking to de-risk and increase commercial attractiveness and licensing potential.
Advising and supporting academic institutions and start-up companies on out-sourcing strategies - looking for cost-effective solutions and accelerating the speed of progression and completion of projects.
Oversight and management of outsourced CMC and preclinical projects.
Undertaking due diligences on behalf of organisations in- and out-licencing development drug candidates.
Exploring innovative business models and opportunities for funding between academia and the out-sourcing network, looking to create collaborative win-win partnerships to progress projects.
Attending conferences and exhibitions on behalf of clients, evaluating new product opportunities and service providers.
Illetrop provides hands-on senior executive support to biotechnology companies. Based in Scotland but operating internationally, Illetrop represents a number of companies from the UK, Asia and mainland Europe.
Intract Pharma Limited is an oral drug delivery licensing and product development company offering a range of proprietary formulation technologies to deliver novel and optimised therapeutics targeted to patient needs. The company is a spin-out of University College London, and is centred around over 15 years of research and innovation from the laboratory of Professor Abdul Basit. Intract's range of formulation technologies includes Phloral™ for colon targeted delivery, and ProRelease™, a versatile microparticulate delivery system.